.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Federal Trade Commission
Dow
Covington
Mallinckrodt
Colorcon
Argus Health
Queensland Health
Merck
Express Scripts

Generated: November 18, 2017

DrugPatentWatch Database Preview

Sanofi-aventis Us Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI-AVENTIS US, and what generic alternatives to SANOFI-AVENTIS US drugs are available?

SANOFI-AVENTIS US has six approved drugs.

There are twenty-nine US patents protecting SANOFI-AVENTIS US drugs.

There are four hundred and twenty-four patent family members on SANOFI-AVENTIS US drugs in forty-four countries and fifty-three supplementary protection certificates in thirteen countries.

Summary for Sanofi-aventis Us

International Patents:424
US Patents:29
Tradenames:4
Ingredients:3
NDAs:6
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007ABRXYesYes► Subscribe► Subscribe► Subscribe
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
SOLIQUA 100/33
insulin glargine; lixisenatide
SOLUTION;SUBCUTANEOUS208673-001Nov 21, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi-aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
SOLUTION;ORAL022157-001Jan 28, 2008► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
Sanofi-aventis Us
XYZAL
levocetirizine dihydrochloride
TABLET;ORAL022064-001May 25, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI-AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
levocetirizine dihydrochloride
Oral Solution0.5 mg/mL
XYZAL
1/14/2009
levocetirizine dihydrochloride
Tablets5 mg
XYZAL
12/17/2007

Non-Orange Book Patents for Sanofi-aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,574,198Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,935,088Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,888,750Pen-type injector► Subscribe
9,205,197Drug delivery device dose setting mechanism► Subscribe
9,623,190Pen-type injector► Subscribe
6,528,486 Peptide agonists of GLP-1 activity► Subscribe
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,905,867Pen-type injector► Subscribe
8,663,175Drive mechanisms suitable for use in drug delivery devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi-aventis Us Drugs

Country Document Number Estimated Expiration
Spain2384963► Subscribe
European Patent Office2480268► Subscribe
Denmark2303369► Subscribe
South Korea20120101679► Subscribe
SloveniaEP1944050► Subscribe
European Patent Office2266648► Subscribe
Denmark1920794► Subscribe
Canada2680437► Subscribe
Japan2014169296► Subscribe
South Korea20130120476► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi-aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
00597Netherlands► SubscribePRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121
/2005Austria► SubscribePRODUCT NAME: NOVOMIX 50 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 50:50; REGISTRATION NO/DATE: EU/1/00/142/011 - EU/1/00/142/016 20051005
/2013Austria► SubscribePRODUCT NAME: LIXISENATID; REGISTRATION NO/DATE: EU/1/12/811/001-005 20130201
C0035France► SubscribePRODUCT NAME: INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/12/807/001 20130121
90036-0Sweden► SubscribePRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
60026Netherlands► SubscribePRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
90021-2Sweden► SubscribePRODUCT NAME: LIXISENATID; REG. NO/DATE: EU/1/12/811/001 20130201
C0044Belgium► SubscribePRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
Chinese Patent Office
Fuji
Colorcon
Covington
US Department of Justice
US Army
Moodys
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot